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Abstract
The acetyltransferase p300 was first identified associated with the adenoviral transforming
protein E1A, suggesting a potential role for p300 in the regulation of cell proliferation. Direct
evidence demonstrating a role for p300 in human tumours was lacking until the recently
publication by Gayther et al, which strongly supports a role for p300 as a tumour
suppressor. The authors identify truncating mutations associated with the loss or mutation of
the second allele in both tumour samples and cell lines, suggesting that loss of p300 may
play a role in the development of a subset of human cancers.
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Post-translational modifications have long been recog-
nised as important in the regulation of protein function
and, until recently, phosphorylation has received the most
interest and attention. Over the past few years, however,
an appreciation of the role of protein acetylation has
increased rapidly, with suggestions that it may rival phos-
phorylation as a critical regulatory modification [1]. CBP
and p300 are two closely related proteins that function to
acetylate target proteins, and they can form interactions
with a growing list of cellular proteins, including transcrip-
tion factors that play important roles in the regulation of
cell growth, such as c-jun, E2F-1, p53, and NF-kB [2].
Although CBP and p300 have been postulated to function
as tumour suppressors, unequivocal evidence from human
malignancies has been lacking. A recent report by Gayther
et al [3] takes a significant step in rectifying this defi-
ciency, with the identification of truncating mutations of
p300 being associated with mutation of the second allele
in both tumour samples and cell lines.
Both CBP and p300 are histone acetyltransferases
(HATs) [4,5], as are a number of other transcriptional
coactivators, including TAF250 and P/CAF [6,7]. One
mechanism through which these HATs are thought to reg-
ulate transcription is the modulation of chromatin struc-
ture, via acetylation of histones, which relaxes the
interaction of histones with DNA. The acetylases can form
a bridge between transcription factors and the basal tran-
scription machinery [2], therefore enhancing transcrip-
tional activation. Since CBP and p300 are present at
limiting concentrations within cells, competition for them
between different transcription factors can facilitate inte-
gration of different signal transduction pathways [8,9].
Although the acetylation of histones is an important prop-
erty of CBP and p300, in terms of mediating transcriptional
activation, there is growing evidence for the importance of
acetylation of other protein targets [1]. These other sub-
strates for CBP and p300 include components of the basal
transcription machinery and transcription factors such ashttp://breast-cancer-research.com/content/2/4/244
p53 and E2F [10,11]. The acetylation of these factors can
modify their activity in either a positive or a negative
manner, and, in the case of p53, this acetylation enhances
sequence-specific DNA binding and transactivation. The
activity of the acetylases is not limited to the transcrip-
tional machinery, however, and the modification of nuclear
import factors and cytoplasmic proteins such as a-tubulin
[12] suggests that acetylation is an important regulatory
modification for a wide range of cellular processes. This is
shown further by the diverse effects of acetylation on
protein function, including DNA binding, protein–protein
interaction and protein stability. Given this broad range of
possible activities for CBP and p300, it is not surprising
that they are thought to play some role in the regulation of
cell division and, as such, are potential candidates for
oncogenes or tumour suppressors. The importance of reg-
ulation of acetylation in the control of tumour development
is also highlighted by the observation that deacetylases
have been found in association with tumour suppressor
proteins. This is probably best illustrated by the interaction
of HDAC1, HDAC2 and HDAC3 with the product of the
retinoblastoma susceptibility gene (pRb), which allows
pRb to function as a tumour suppressor [13].
The first suggestion that CBP and p300 may regulate
growth and function as tumour suppressors was provided
by studies of adenovirus E1A’s transforming properties.
Both CBP and p300 can interact with E1A, and this inter-
action perturbs the CBP/p300 activity [14]. The impor-
tance of this interaction with E1A was demonstrated by
studies showing that an E1A mutant which is unable to
bind to pRb but retains p300 binding was still capable of
stimulating entry into DNA synthesis in rodent cells [15].
Although interpretation of this work is complicated by con-
fusion regarding whether E1A inhibits or enhances
CBP/p300 activity, the data suggest that disruption of
CBP/p300 activity may stimulate proliferation, indicating
that CBP/p300 may inhibit proliferation and function as
tumour suppressors. Analysis of patients with Ruben-
stein–Taybi syndrome provided further evidence for a role
for CBP in tumour suppression. Individuals with this condi-
tion lack one functional allele of CBP, display a variety of
developmental syndromes and show a predisposition to
cancer [16]. Although CBP and p300 are frequently dis-
cussed as interchangeable proteins, analysis of knockout
mice suggests that, despite a degree of functional overlap,
the two proteins can perform unique functions. Interest-
ingly, mice heterozygous for loss of CBP develop tumours,
similar to the patients with Rubenstein–Taybi syndrome,
whereas mice heterozygous for loss of p300 show no
increased incidence of malignancy [17].
Despite the current lack of direct evidence for p300 acting
as a tumour suppressor in the mouse model, p300 itself
has been implicated, by loss of heterozygosity studies, in a
number of different cancer types in humans, including
glioblastomas and colorectal tumours. A single case of
missense mutation coupled with the loss of the other allele
has also been reported for a gastric and colorectal tumour
sample [18]. Although the implications of these mutations
are provocative, it was unclear whether the mutations
would impair the function of the resultant proteins. The
mutations described by Gayther et al [3] could dispel
these doubts because a number of them would clearly
abrogate the normal function of the protein. These workers
screened 193 tumour samples or cell lines, and identified
six mutations that would result in the expression of a trun-
cated protein, two of which were in primary tumours (col-
orectal and breast) and the other four in cell lines
(colorectal, breast and pancreatic). Inactivation of the
second allele was found for five out of these six samples.
In addition to these truncation mutations, an insertion (in a
primary breast cancer) and three missense mutations (in
one primary and two colorectal cell lines) were identified;
two of these were associated with deletion of the second
allele. Of the truncations, three occur upstream of the HAT
domain, and would clearly abrogate their normal function.
The other truncations may also be inactivating despite
retaining the HAT domain because they lose the ZZ/TAZ
domain, which is important for interaction with a number of
transcription factors, including p53 [19]. The status of the
missense mutations in terms of the effects on gene func-
tion is unknown, but the insertion of six amino acids
occurs in the HAT domain and may well abolish HAT activ-
ity. Most of the p300 mutations would clearly lead to loss
of function, supporting the proposal that loss of p300
activity contributes to tumour development. However, the
study from Gayther et al [3] also indicated that p300
mutations are relatively rare in tumours (10/193 samples,
consisting of 6 truncations, 1 insertion and 3 missense
mutations). It would be interesting to determine whether
CBP is mutated in any of the tumours with wild-type p300
or whether there are other, as yet unknown, p300-related
proteins that may be mutated during tumorigenesis.
The next important question to be addressed is how p300
mediates its tumour suppressive properties. One attractive
hypothesis would be that, since p300 is involved in
enhancing the transcriptional activity of p53 [10,19–21],
loss of its function would impair the ability of p53 to func-
tion as a tumour suppressor. However, a p53-independent
tumour suppressor function for p300 is suggested by
studies showing that the proliferative advantage of pertur-
bation of p300 by E1A occurs even in the absence of
functional p53 [15]. Gayther et al addressed this question
in the human cancer cells by testing the samples for the
presence of p53 mutations. Three of the six samples with
mutations leading to truncations of p300 contained p53
mutation, indicating that loss of p300 does not eliminate
the need for loss of p53 during tumour development.
Nevertheless, a role for p53 is not completely eliminated; it
is possible that loss of p300 impairs p53 function onlyBreast Cancer Research    Vol 2 No 4 Phillips and Vousden
partially and, despite giving the cell a selective advantage,
there would still be selective pressure to lose p53 function
completely. Further work is clearly required to understand
how loss of p300 may contribute to tumour development,
but there is an abundance of other target proteins with
which it can interact that may mediate this phenotype.
Gayther et al [3] strongly support a role for p300 as a
tumour suppressor, and reveal an interesting dual role for
CBP/p300 in the development of human cancer. In addi-
tion to functioning as tumour suppressors, both CBP and
p300 can, in certain leukaemia strains, be oncogenic as a
result of fusion to other proteins [2,22,23]. In this case,
these mutations are of gain-of-function type, which pre-
sumably function by inappropriately enhancing activation
of certain transcription programmes leading to increased
proliferation. Identification of the protein substrates of
p300 and CBP that mediate the positive or negative regu-
lation of cell growth is complicated by the difficulty of
assigning which acetylase in vivo is responsible for the
acetylation of a protein. However, the recent generation of
specific synthetic inhibitors of acetylases [24] may allow
the identification of pathways regulated specifically by
p300 and CBP, and may shed light on how they function
as tumour suppressors.
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